文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

作者信息

Beurel Eleonore, Grieco Steven F, Jope Richard S

机构信息

Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL 33136, United States; Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL 33136, United States.

Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL 33136, United States; Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL 33136, United States.

出版信息

Pharmacol Ther. 2015 Apr;148:114-31. doi: 10.1016/j.pharmthera.2014.11.016. Epub 2014 Nov 27.


DOI:10.1016/j.pharmthera.2014.11.016
PMID:25435019
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4340754/
Abstract

Glycogen synthase kinase-3 (GSK3) may be the busiest kinase in most cells, with over 100 known substrates to deal with. How does GSK3 maintain control to selectively phosphorylate each substrate, and why was it evolutionarily favorable for GSK3 to assume such a large responsibility? GSK3 must be particularly adaptable for incorporating new substrates into its repertoire, and we discuss the distinct properties of GSK3 that may contribute to its capacity to fulfill its roles in multiple signaling pathways. The mechanisms regulating GSK3 (predominantly post-translational modifications, substrate priming, cellular trafficking, protein complexes) have been reviewed previously, so here we focus on newly identified complexities in these mechanisms, how each of these regulatory mechanism contributes to the ability of GSK3 to select which substrates to phosphorylate, and how these mechanisms may have contributed to its adaptability as new substrates evolved. The current understanding of the mechanisms regulating GSK3 is reviewed, as are emerging topics in the actions of GSK3, particularly its interactions with receptors and receptor-coupled signal transduction events, and differential actions and regulation of the two GSK3 isoforms, GSK3α and GSK3β. Another remarkable characteristic of GSK3 is its involvement in many prevalent disorders, including psychiatric and neurological diseases, inflammatory diseases, cancer, and others. We address the feasibility of targeting GSK3 therapeutically, and provide an update of its involvement in the etiology and treatment of several disorders.

摘要

相似文献

[1]
Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

Pharmacol Ther. 2015-4

[2]
GSK3β isoform-selective regulation of depression, memory and hippocampal cell proliferation.

Genes Brain Behav. 2016-3

[3]
Advances in the Therapeutic Potential of Inhibitors Targeting Glycogen Synthase Kinase 3 in Inflammatory Diseases.

Mini Rev Med Chem. 2023

[4]
Differential regulation of STAT family members by glycogen synthase kinase-3.

J Biol Chem. 2008-8-8

[5]
Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain.

J Neurochem. 2010-10-5

[6]
Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle.

Am J Physiol Endocrinol Metab. 2005-6

[7]
Anesthesia and post-mortem interval profoundly influence the regulatory serine phosphorylation of glycogen synthase kinase-3 in mouse brain.

J Neurochem. 2005-2

[8]
Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis.

Br J Pharmacol. 2008-3

[9]
GSK3 in Alzheimer's disease: mind the isoforms.

J Alzheimers Dis. 2014

[10]
Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.

Curr Drug Targets. 2006-11

引用本文的文献

[1]
ApoE4 Upregulates GSK-3β to Aggravate Alzheimer-Like Pathologies and Cognitive Impairment in Type 2 Diabetic Mice.

CNS Neurosci Ther. 2025-9

[2]
The role of LKB1 in prostate cancer: implications for tumor progression and therapy.

Front Cell Dev Biol. 2025-8-12

[3]
Living on the Edge: ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target.

Antioxidants (Basel). 2025-8-16

[4]
Integrated multi-omics characterization across clinically relevant subgroups of long COVID.

Natl Sci Rev. 2024-11-15

[5]
The kinase GSK-3 alters the RNA-binding protein landscape of lipid metabolism transcripts leading to altered expression in the C. elegans nervous system.

Nucleic Acids Res. 2025-8-11

[6]
Breast Cancer Cell Line-Specific Responses to Insulin: Effects on Proliferation and Migration.

Int J Mol Sci. 2025-8-4

[7]
Geraniin Alleviates High-Fat Diet-Induced Atherosclerosis in Mice.

Food Sci Nutr. 2025-7-25

[8]
MAPK, PI3K/Akt Pathways, and GSK-3β Activity in Severe Acute Heart Failure in Intensive Care Patients: An Updated Review.

J Cardiovasc Dev Dis. 2025-7-10

[9]
Metabolic plasticity: an evolutionary perspective on metabolic and circadian dysregulation in bipolar disorder.

Mol Psychiatry. 2025-7-19

[10]
Human glycogenins maintain glucose homeostasis by regulating glycogen metabolism.

Nat Commun. 2025-7-16

本文引用的文献

[1]
CDK5 activator protein p25 preferentially binds and activates GSK3β.

Proc Natl Acad Sci U S A. 2014-11-11

[2]
Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?

Int J Biol Sci. 2014-9-10

[3]
Dynamic range of GSK3α not GSK3β is essential for bidirectional synaptic plasticity at hippocampal CA3-CA1 synapses.

Hippocampus. 2014-12

[4]
Effect of glycogen synthase kinase-3 inactivation on mouse mammary gland development and oncogenesis.

Oncogene. 2015-7

[5]
Regulation of MDA-MB-231 cell proliferation by GSK-3β involves epigenetic modifications under high glucose conditions.

Exp Cell Res. 2014-4-1

[6]
A new avenue for lithium: intervention in traumatic brain injury.

ACS Chem Neurosci. 2014-6-18

[7]
Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells.

Cell Death Dis. 2014-3-27

[8]
Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6.

Elife. 2014-3-18

[9]
A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

Mov Disord. 2014-4

[10]
Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial.

Mov Disord. 2014-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索